Apellis Pharmaceuticals Shares Down 5.8% Premarket After EU Panel Confirms Negative Opinion for Eye Disease Drug
apellis pharmaceuticals股價在歐洲監管機構確認對眼病藥物發表負面意見後,盤前下跌5.8%
Apellis Pharmaceuticals Shares Down 5.8% Premarket After EU Panel Confirms Negative Opinion for Eye Disease Drug
apellis pharmaceuticals股價在歐洲監管機構確認對眼病藥物發表負面意見後,盤前下跌5.8%
譯文內容由第三人軟體翻譯。